Neurenati Therapeutics Appoints Dr. Marielle Cohard-Radice to Board

Neurenati Therapeutics, a company dedicated to the treatment of pediatric rare diseases, has announced the addition of an experienced executive to its board of directors. Dr. Marielle Cohard-Radice, an accomplished gastroenterologist with over thirty years of experience across various therapeutic areas, has joined as an independent board member. Currently, she serves as the Executive Vice-president and Global Head of Development Operations at Daiichi Sankyo.

Dr. Cohard-Radice's extensive expertise is expected to significantly enhance Neurenati's clinical development strategies. Maxime Ranger, the CEO of Neurenati, expressed his enthusiasm for her appointment, emphasizing her critical role in improving the company's clinical development success rates.

Dr. Cohard-Radice also commented on her new role, expressing her support for Neurenati’s mission. She highlighted the importance of providing non-surgical treatment options for newborns suffering from Hirschsprung's disease. She noted that preclinical efficacy data indicates that Neurenati’s product, NEU-001, shows promise in regenerating the enteric nervous system in affected children.

In addition to Dr. Cohard-Radice, Dr. Alexandre Lebeaut, another independent board member, will work alongside her to help the company establish its scientific and clinical advisory board in the near future.

Neurenati has also announced a significant new appointment to its management team. Dr. Marie-Eve Bordeleau has been named Senior Director of Preclinical Development. Before joining Neurenati, Dr. Bordeleau was the Deputy Director of the Molecular Genetics of Stem Cells Research Unit at IRIC, Université de Montréal, under the supervision of Dr. Guy Sauvageau. In her new role, she will oversee the entire preclinical program and manage the manufacturing of NEU-001.

Neurenati Therapeutics, based in Québec, focuses on developing treatments for rare diseases. The company’s primary technology aims to address Hirschsprung disease (HSCR), a severe gastrointestinal birth defect characterized by the absence of nerves in parts of the lower gastrointestinal tract. Neurenati is developing an innovative therapy involving growth factors to treat newborns with HSCR, potentially eliminating the need for surgery and reducing associated risks.

Neurenati continues to advance its mission of developing effective therapies for rare pediatric diseases, leveraging the expertise of its new board and management team members to drive future successes.